WuXi AppTec Co Ltd - Asset Resilience Ratio

Latest as of June 2025: 3.51%

WuXi AppTec Co Ltd (603259) has an Asset Resilience Ratio of 3.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 603259 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥2.94 Billion
≈ $430.57 Million USD Cash + Short-term Investments

Total Assets

CN¥83.82 Billion
≈ $12.27 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how WuXi AppTec Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is WuXi AppTec Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down WuXi AppTec Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see WuXi AppTec Co Ltd (603259) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.94 Billion 3.51%
Total Liquid Assets CN¥2.94 Billion 3.51%

Asset Resilience Insights

  • Limited Liquidity: WuXi AppTec Co Ltd maintains only 3.51% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

WuXi AppTec Co Ltd Industry Peers by Asset Resilience Ratio

Compare WuXi AppTec Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Genetic Signatures Ltd
AU:GSS
Diagnostics & Research 60.91%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Cryosite Ltd
AU:CTE
Diagnostics & Research 5.65%
Inoviq Ltd
AU:IIQ
Diagnostics & Research 56.29%

Annual Asset Resilience Ratio for WuXi AppTec Co Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for WuXi AppTec Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.54% CN¥1.23 Billion
≈ $180.57 Million
CN¥80.33 Billion
≈ $11.75 Billion
+0.47pp
2023-12-31 1.07% CN¥785.78 Million
≈ $114.98 Million
CN¥73.67 Billion
≈ $10.78 Billion
+1.06pp
2022-12-31 0.00% CN¥2.00 Million
≈ $292.66K
CN¥64.69 Billion
≈ $9.47 Billion
-0.95pp
2021-12-31 0.96% CN¥527.29 Million
≈ $77.16 Million
CN¥55.13 Billion
≈ $8.07 Billion
-9.02pp
2020-12-31 9.98% CN¥4.62 Billion
≈ $675.72 Million
CN¥46.29 Billion
≈ $6.77 Billion
+4.16pp
2019-12-31 5.82% CN¥1.70 Billion
≈ $249.00 Million
CN¥29.24 Billion
≈ $4.28 Billion
-3.56pp
2018-12-31 9.38% CN¥2.13 Billion
≈ $311.00 Million
CN¥22.67 Billion
≈ $3.32 Billion
+9.26pp
2017-12-31 0.12% CN¥14.74 Million
≈ $2.16 Million
CN¥12.58 Billion
≈ $1.84 Billion
-3.98pp
2016-12-31 4.10% CN¥434.19 Million
≈ $63.54 Million
CN¥10.59 Billion
≈ $1.55 Billion
+1.10pp
2015-12-31 3.00% CN¥290.84 Million
≈ $42.56 Million
CN¥9.69 Billion
≈ $1.42 Billion
-3.25pp
2014-12-31 6.25% CN¥472.59 Million
≈ $69.15 Million
CN¥7.56 Billion
≈ $1.11 Billion
--
pp = percentage points

About WuXi AppTec Co Ltd

SHG:603259 China Diagnostics & Research
Market Cap
$35.78 Billion
CN¥244.48 Billion CNY
Market Cap Rank
#761 Global
#50 in China
Share Price
CN¥98.85
Change (1 day)
-0.90%
52-Week Range
CN¥64.00 - CN¥112.85
All Time High
CN¥165.00
About

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more